Previous Close | 11.17 |
Open | 11.17 |
Bid | 10.90 |
Ask | 12.90 |
Strike | 17.00 |
Expire Date | 2026-01-16 |
Day's Range | 11.17 - 11.17 |
Contract Range | N/A |
Volume | |
Open Interest | 10 |
ROCKVILLE, Md. & EDMONTON, Alberta, May 30, 2024--Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
ROCKVILLE, Md. & EDMONTON, Alberta, May 14, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program.